Regenxbio (RGNX) Tops Q4 EPS by $1.96

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of $6.67, $1.96 better than the analyst estimate of $4.71. Revenue for the quarter came in at $398.7 million versus the consensus estimate of $271.74 million.

Based on its current operating plan, REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $849.3 million as of December 31, 2021 to fund its operations, including the completion of its internal manufacturing capabilities and clinical advancement of its product candidates, into 2025.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Anthropic delays planned IPO from October to November - WSJ